COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial

Marquita Camilleri^{1

2}, Jonathan Sive¹, William Wilson³, Gavin Pang³, Richard Jenner³, Elizabeth Phillips⁴, Rakesh Popat^{1

2}, Karthik Ramasamy^{5

6}, Ceri Bygrave⁷, Tushhar Dadaga³, Matthew Streetly⁸, James Cavenagh⁹, Mike Chapman¹⁰, Sally Barrington¹¹, Lucy Pike¹¹, Roger Owen¹², Laura Clifton-Hadley³, Kwee Yong^{1

2}

Affiliations

¹ Haematology Department, University College Hospitals, London, UK.
² Cancer Institute, University College London, London, UK.
³ Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.
⁴ Division of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester, UK.
⁵ Haematology Department, Oxford University Hospitals NHS Trust, Oxford, UK.
⁶ Radcliffe Department of Medicine, Oxford University, Oxford, UK.
⁷ Haematology Department, University Hospital of Wales, Wales, UK.
⁸ Haematology Department, Guys and St Thomas' NHS Trust, London, UK.
⁹ Haematology Department, Bart's Health NHS Trust, London, UK.
¹⁰ Haematology Department, Cambridge Institute for Medical Research, Cambridge, UK.
¹¹ School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
¹² HMDS Laboratory, St James' Institute of Oncology, Leeds, UK.

Clinical Trial

Marquita Camilleri et al. Br J Haematol. 2021 Jan.

. 2021 Jan;192(1):e14-e16.

doi: 10.1111/bjh.17168. Epub 2020 Nov 21.

¹ Haematology Department, University College Hospitals, London, UK.
² Cancer Institute, University College London, London, UK.
³ Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.
⁴ Division of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester, UK.
⁵ Haematology Department, Oxford University Hospitals NHS Trust, Oxford, UK.
⁶ Radcliffe Department of Medicine, Oxford University, Oxford, UK.
⁷ Haematology Department, University Hospital of Wales, Wales, UK.
⁸ Haematology Department, Guys and St Thomas' NHS Trust, London, UK.
⁹ Haematology Department, Bart's Health NHS Trust, London, UK.
¹⁰ Haematology Department, Cambridge Institute for Medical Research, Cambridge, UK.
¹¹ School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
¹² HMDS Laboratory, St James' Institute of Oncology, Leeds, UK.

No abstract available

Keywords: COVID-19; clinical trials; myeloma.

Figures

1. World Health Organisation . WHO Coronavirus Disease (COVID‐19) Dashboard. [cited 2020 August 28]. Available from: https://covid19.who.int/.
1. Public Health England and NHSX . Coronavirus (COVID‐19) in the UK. [cited 2020 August 27]. Available from: https://coronavirus.data.gov.uk/.
1. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID‐19‐related death using OpenSAFELY. Nature. 2020;584:430–6. - PMC - PubMed
1. Fox TA, Troy‐Barnes E, Kirkwood AA, Chan WY, Day JW, Chavda SJ, et al. Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy. Br J Haematol. 2020. 10.1111/bjh.17027. - DOI - PMC - PubMed
1. European Society for Medical Oncology – ESMO . ESMO Management and Treatment Adapted Recommendations in the COVID‐19 Era: Multiple Myeloma. Available from: https://www.esmo.org/guidelines/cancer‐patient‐management‐during‐the‐cov... [cited 2020 August 28].